CENTRAL TRUST Co lessened its stake in shares of CME Group Inc (NASDAQ:CME) by 52.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,607 shares of the financial services provider’s stock after selling 5,010 shares during the quarter. CENTRAL TRUST Co’s holdings in CME Group were worth $758,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Kentucky Retirement Systems purchased a new stake in CME Group in the 3rd quarter valued at $2,042,000. Nordea Investment Management AB grew its holdings in CME Group by 6.4% in the 3rd quarter. Nordea Investment Management AB now owns 125,008 shares of the financial services provider’s stock valued at $21,281,000 after buying an additional 7,557 shares in the last quarter. Financial Enhancement Group LLC acquired a new position in shares of CME Group in the 3rd quarter valued at $393,000. Legal & General Group Plc lifted its stake in shares of CME Group by 2.2% in the 3rd quarter. Legal & General Group Plc now owns 1,612,654 shares of the financial services provider’s stock valued at $274,515,000 after purchasing an additional 34,772 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of CME Group by 20.5% in the 3rd quarter. Morgan Stanley now owns 1,118,708 shares of the financial services provider’s stock valued at $190,415,000 after purchasing an additional 190,256 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.
In other CME Group news, Director Ronald A. Pankau sold 200 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $182.90, for a total value of $36,580.00. Following the sale, the director now owns 3,600 shares of the company’s stock, valued at approximately $658,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kathleen M. Cronin sold 4,960 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $186.69, for a total value of $925,982.40. Following the completion of the sale, the insider now directly owns 49,337 shares in the company, valued at approximately $9,210,724.53. The disclosure for this sale can be found here. Insiders sold a total of 43,449 shares of company stock worth $7,665,179 in the last ninety days. 1.20% of the stock is owned by corporate insiders.
Several equities analysts have recently commented on the company. BidaskClub lowered CME Group from a “sell” rating to a “strong sell” rating in a research note on Friday, March 22nd. Zacks Investment Research lowered CME Group from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Citigroup set a $202.00 price target on CME Group and gave the company a “buy” rating in a research note on Thursday, May 2nd. UBS Group decreased their target price on CME Group from $179.00 to $175.00 and set a “neutral” rating on the stock in a research note on Thursday, May 2nd. Finally, Barclays decreased their target price on CME Group from $210.00 to $193.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 26th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $189.71.
CME stock traded down $0.75 during mid-day trading on Wednesday, reaching $185.82. The company had a trading volume of 754,971 shares, compared to its average volume of 1,768,266. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market capitalization of $66.34 billion, a P/E ratio of 27.25, a P/E/G ratio of 4.21 and a beta of 0.32. CME Group Inc has a fifty-two week low of $157.21 and a fifty-two week high of $197.08.
CME Group (NASDAQ:CME) last posted its quarterly earnings results on Wednesday, May 1st. The financial services provider reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.02. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.19 billion. CME Group had a return on equity of 9.29% and a net margin of 42.47%. CME Group’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.86 EPS. On average, analysts expect that CME Group Inc will post 6.62 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.61%. The ex-dividend date of this dividend is Friday, June 7th. CME Group’s dividend payout ratio is currently 43.99%.
WARNING: “CME Group Inc (NASDAQ:CME) Stake Lowered by CENTRAL TRUST Co” was originally reported by Sundance Herald and is owned by of Sundance Herald. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://sundanceherald.com/2019/05/22/cme-group-inc-cme-shares-sold-by-central-trust-co.html.
CME Group Company Profile
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.
Featured Article: Why are trading ranges significant?
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.